Bystander effect of purine nucleoside analogues in HSV-1tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues

Gene Therapy

Volumn 6, Issue 2, 1999, Pages 162-170

  Degreve B ^a   De Clercq, E ^a   Balzarini, J ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiherpetic nucleoside analogues; Bystander effect; Gene therapy; HSV 1 thymidine kinase

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; BUCICLOVIR; GANCICLOVIR; LOBUCAVIR; PURINE NUCLEOSIDE DERIVATIVE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; THYMIDINE KINASE;

ARTICLE; AUTORADIOGRAPHY; CELL JUNCTION; CELL POPULATION; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE THERAPY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SOLID TUMOR; SUICIDE GENE; TUMOR CELL;

ANTIVIRAL AGENTS; AUTORADIOGRAPHY; GANCICLOVIR; GENE THERAPY; GUANINE; HUMANS; OSTEOSARCOMA; PURINE NUCLEOSIDES; PYRIMIDINE NUCLEOSIDES; THYMIDINE KINASE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 18544405495     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300806     Document Type: Article

References (37)

1. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
2. Ram Z et al. In situ retrovirus-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83-88.
3. Human gene marker/therapy clinical protocols. Hum Gene Ther 1996; 7: 1621-1647.
4. Balzarini J, De Clercq E, Ayusawa D, Seno T. Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2'-deoxyuridine and related compounds. FEBS Lett 1985; 185: 95-100.
5. Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem 1993; 268: 6332-6337.
6. Balzarini J, Bohman C, Walker RT, De Clercq E. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol Pharmacol 1994; 45: 1253-1258.
7. Balzarini J et al. Novel (E)-5-(2-iodovinyl)-2'-deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors. Gene Therapy 1995; 2: 317-322.
8. Balzarini J et al. Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1 thymidine kinase gene-transfected tumor cells. Gene Therapy 1998; 5: 419-426.
9. Degrève B et al. Varicella-zoster virus thymidine kinase gene and antiherpetic pyrimidine nucleoside analogues in a combined gene/chemotherapy treatment for cancer. Gene Therapy 1997; 4: 1107-1114.
10. Short MP et al. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J Neurosci Res 1990; 27: 427-433.
11. Smythe WR et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 1994; 57: 1395-1401.
12. Ram Z et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med 1997; 12: 1354-1361.
13. Freeman SM et al. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
14. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
15. Ishii-Morita H et al. Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Therapy 1997; 4: 244-251.
16. Mesnil M et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835.
17. Elshami AA et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85-92.
18. Fick J et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 1995; 92: 11071-11075.
19. Dilber MS et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res 1997; 57: 1523-1528.
20. Park JY et al. Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy. Gene Therapy 1997; 4: 909-917.
21. Yamasaki H. Gap junctional intercellular communication and carcinogenesis. Carcinogenesis 1990; 11: 1051-1058.
22. Freeman SM et al. The treatment of ovarian cancer with a gene-modified cancer vaccine: a phase I study. Hum Gene Ther 1995; 6: 927-939.
23. Marini III FC, Nelson JA, Lapeyre J-N. Assessment of bystander effect potency produced by intratumoral implantation of HSVtk-expressing cells using surrogate marker secretion to monitor tumor growth kinetics. Gene Therapy 1995; 2: 655-659.
24. Caruso M et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci USA 1993; 90: 7024-7028.
25. Vile RG et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
26. Ram Z et al. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J Neurosurg 1994; 81: 256-260.
27. Balzarini J et al. 5-Substituted 2'-deoxyuridines: correlation between inhibition of tumor cell growth and inhibition of thymidine kinase and thymidylate synthetase. Biochem Pharmacol 1982; 31: 3673-3682.
28. Subak-Sharpe JH, Burk RR, Pitts JD. Metabolic cooperation by cell to cell transfer between genetically different mammalian cells. Heredity 1966; 21: 342-343.
29. Subak-Sharpe JH, Burk RR, Pitts JD. Metabolic cooperation between biochemically marked mammalian cells in tissue culture. J Cell Sci 1969; 4: 353-367.
30. Fujimoto WY, Subak-Sharpe JH, Seegmiller JE. Hypoxanthineguanine phosphoribosyltransferase deficiency: chemical agents selective for mutant or normal cultured fibroblasts in mixed and heterozygote cultures. Proc Natl Acad Sci USA 1971; 7: 1516-1519.
31. Myhr BC, DiPaolo JA. Requirement for cell dispersion prior to selection of induced azaguanine-resistant colonies of Chinese hamster cells. Genetics 1975; 80: 157-169.
32. Dickerman LH, Tischfield JA. Comparative effects of adenine analogs upon metabolic cooperation between hamster cells with different levels of adenine phosphoryibosyltransferase activity. Mutat Res 1978; 49: 83-94.
33. Bevans CG, Kordel M, Rhee SK, Harris AL. Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules. J Biol Chem 1998; 273: 2808-2816.
34. Cao R et al. A quantitative analysis of connexin-specific permeability differences of gap junctions expressed in HeLa transfectants and Xenopus oocytes. J Cell Sci 1998; 111: 31-43.
35. Veenstra RD et al. Selectivity of connexin-specific gap junctions does not correlate with channel conductance. Circulation Res 1995; 77: 1156-1165.
36. Veenstra RD. Size and selectivity of gap junction channels formed from different connexins. J Bioenerg Biomembr 1996; 28: 327-337.
37. Degrève B et al. Differential intracellular compartmentation of herpetic thymidine kinases (tks) in tk gene-transfected tumor cells. Molecular characterization of the nuclear localization signal of herpes simplex virus type 1 tk. J Virol 1998; 72 (in press).